[Agents for the metabolic correction of myocardial energy metabolism in treating patients with ischemic heart disease].

Correction of the metabolic link of the natural course of ischemic heart disease (IHD) was found out to be a real reserve of enhancement of therapy efficiency in treating this condition. A total of 137 IHD patients were examined, presenting with functional class II-III exertional angina, their age ranging between 67 to 86 years. Kinds of metabolic complexes to be used in IHD treatment included amino acids, antioxidants, cofactors, energy-providing compounds that enhance efficiency of basic methods of IHD therapy.

[An amino acid metabolic complex in optimizing the cardiac hemodynamic characteristics of patients with ischemic heart disease].

On the basis of findings from examination of 82 patients with ischemic heart disease presenting with exertional angina, functional class II-III, aged 62-86 years, efficacy was studied of an amino acid metabolic complex consisting of glutamic acid and methionine combined with basic antianginal drugs and single basic therapy with nitrates and calcium antagonists. Criteria for efficacy were condition of central cardiohemodynamics and inotropic indices. Glutamic acid and methionine combined with basic agents were found to make for enhancement of contractile function of ischemized myocardium, with the left ventricular local contractility being improved against the background of reduction in postload.

[The optimization of the hemodynamic characteristics in patients with ischemic heart disease and circulatory failure by using a substrate-coenzyme complex].

On the basis of findings from evaluation of 65 patients with ischemic heart disease presenting with functional class II-III effort angina and FC II-III circulatory insufficiency (NYHA) a comparative assessment was carried out of efficacy of combined therapy involving basic antianginal agents and glucose-insulin-potassium mixture plus glutaminic acid versus solitary basic therapy. It has been shown that combined versus basic therapy is much more capable of restoring cardiohemodynamic interrelations. This was evidenced by a significant reduction of the postexercise level, improvement in the coordination of work of the arterial system, and augmentation of the left ventricular inotropic function.

[The use of the new cardioprotective agent thiotriazoline in the therapy of ischemic heart disease in older patients].

The effect of tiotriazolin on the efficiency of antianginal therapy in aged patients with cardiac disease CD is studied. Clinical tests, functional (ECG, electrocardiotopography, cardiohemodynamics, etc.) and biochemical (indices of lipid peroxidation activity) methods of control were used as criteria of the treatment efficiency.